Crossmark

A coordinated approach for managing polypharmacy among children with medical complexity: rationale and design of the Pediatric Medication Therapy Management (pMTM) randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s12913-023-09439-y

Published Online: 2023-04-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Orth, Lucas E. http://orcid.org/0000-0003-1173-2146
Feudtner, Chris http://orcid.org/0000-0002-5879-0434
Kempe, Allison

Morris, Megan A.

Colborn, Kathryn L.

Gritz, R. Mark

Linnebur, Sunny A. http://orcid.org/0000-0002-3271-7407
Begum, Anowara

Feinstein, James A. http://orcid.org/0000-0003-3074-8805
Funding

Funding for this research was provided by:

Agency for Healthcare Research and Quality,United States (R01HS028979-01A1, R01HS028979-01A1, R01HS028979-01A1, R01HS028979-01A1, R01HS028979-01A1, R01HS028979-01A1, R01HS028979-01A1)
License Information

Text and Data Mining valid from 2023-04-29

Version of Record valid from 2023-04-29
More Information

Article History

Received: 15 March 2023

Accepted: 24 April 2023

First Online: 29 April 2023

Declarations

:

: Ethics approval was granted by the Colorado Multiple Institutional Review Board (COMIRB #22–2423 and #23–0109). Written informed consent will be obtained from all patients and their legal guardian(s). Written assent of pediatric patients will also be obtained using an assent form for children ages 7–12 years old and a joint assent-consent form for children ages 13–18 years old. All experiments will be performed in accordance with relevant guidelines and regulations including the Declaration of Helsinki.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below